Table 1 Demographic characteristics of Paxlovid and Non-Paxlovid
Before PSM matching | After PSM matching | |||||
|---|---|---|---|---|---|---|
Paxlovid N = 8805 | Non-Paxlovid N = 110,551 | SMD | Paxlovid N = 8803 | Non-Paxlovid N = 8803 | SMD | |
Age, mean ± SD | 54.4 ± 15.7 | 41.9 ± 21.9 | 0.657 | 54.4 ± 15.8 | 54.3 ± 16.2 | 0.003 |
Sex | ||||||
Female | 6134 (69.7) | 74444 (67.3) | 0.05 | 6134 (69.7) | 6163 (70.0) | 0.007 |
Male | 2668 (30.3) | 36096 (32.7) | 0.051 | 2668 (30.3) | 2640 (30.0) | 0.007 |
Race | ||||||
White | 7239 (82.2) | 76172 (68.9) | 0.314 | 7237 (82.2) | 7261 (82.5) | 0.007 |
Black or African American | 653 (7.4) | 16,000 (14.5) | 0.227 | 653 (7.4) | 645 (7.3) | 0.003 |
Asian characteristic(s) | 252 (2.9) | 3162 (2.9) | < 0.001 | 252 (2.9) | 248 (2.8) | 0.003 |
BMI | 3,266 | 39,979 | 3,266 | 3,175 | ||
< 18.5 | 101 (1.1) | 5681 (5.1) | 0.230 | 101 (1.1) | 36 (0.4) | 0.084 |
18.5–24.9 | 925 (10.5) | 11987 (10.8) | 0.011 | 925 (10.5) | 846 (9.6) | 0.03 |
25–29.9 | 1253 (14.2) | 12510 (11.3) | 0.087 | 1253 (14.2) | 1170 (13.3) | 0.027 |
≥ 30 | 1512 (17.2) | 16056 (14.5) | 0.073 | 1512 (17.2) | 1517 (17.2) | 0.002 |
Mean ± SD | 29.8 ± 6.8 | 27.9 ± 7.8 | 0.258 | 29.8 ± 6.8 | 30.0 ± 6.7 | 0.033 |
Socioeconomic status | ||||||
Housing/economic circumstances problem | 27 (0.3) | 431 (0.4) | 0.014 | 27 (0.3) | 14 (0.2) | 0.031 |
Problems related to education and literacy | 12 (0.1) | 153 (0.1) | 0.001 | 12 (0.1) | 10 (0.1) | 0.006 |
Employment or unemployment problems | 12 (0.1) | 156 (0.1) | 0.001 | 12 (0.1) | 10 (0.1) | 0.006 |
Occupational exposure to risk factors | 10 (0.1) | 43 (0.0) | 0.027 | 10 (0.1) | 10 (0.1) | < 0.001 |
Comorbidities | ||||||
Hypertension | 3113 (35.4) | 24,605 (22.3) | 0.292 | 3113 (35.4) | 3092 (35.1) | 0.005 |
Type 2 diabetes mellitus | 1450 (16.5) | 12,122 (11.0) | 0.16 | 1450 (16.5) | 1428 (16.2) | 0.007 |
Chronic kidney disease | 332 (3.8) | 4253 (3.8) | 0.004 | 332 (3.8) | 287 (3.3) | 0.028 |
Nicotine dependence | 368 (4.2) | 5261 (4.8) | 0.028 | 368 (4.2) | 305 (3.5) | 0.037 |
Overweight | 109 (1.2) | 1328 (1.2) | 0.003 | 109 (1.2) | 76 (0.9) | 0.037 |
Alcohol-related disorders | 65 (0.7) | 1084 (1.0) | 0.026 | 65 (0.7) | 65 (0.7) | < 0.001 |
Medications | ||||||
Etanercept | 51 (0.6) | 497 (0.4) | 0.018 | 51 (0.6) | 50 (0.6) | 0.002 |
Adalimumab | 151 (1.7) | 1478 (1.3) | 0.031 | 151 (1.7) | 125 (1.4) | 0.024 |
Golimumab | 21 (0.2) | 136 (0.1) | 0.027 | 21 (0.2) | 16 (0.2) | 0.012 |
Rituximab | 25 (0.3) | 500 (0.5) | 0.028 | 25 (0.3) | 29 (0.3) | 0.008 |
Tocilizumab | 17 (0.2) | 159 (0.1) | 0.012 | 17 (0.2) | 17 (0.2) | < 0.001 |
Abatacept | 20 (0.2) | 227 (0.2) | 0.005 | 20 (0.2) | 17 (0.2) | 0.007 |
Tofacitinib | 19 (0.2) | 313 (0.3) | 0.013 | 19 (0.2) | 18 (0.2) | 0.002 |
Corticosteroids | 2209 (25.1) | 27,193 (24.6) | 0.011 | 2209 (25.1) | 2099 (23.8) | 0.029 |
Medical utilization | ||||||
Ambulatory | 8412 (95.5) | 92,022 (83.2) | 0.407 | 8410 (95.5) | 8355 (94.9) | 0.029 |
Emergency | 1502 (17.1) | 24,233 (21.9) | 0.123 | 1502 (17.1) | 1370 (15.6) | 0.041 |
Inpatient Encounter | 529 (6.0) | 10931 (9.9) | 0.144 | 529 (6.0) | 527 (6.0) | 0.001 |